

Table S1 Clinicopathologic characteristics of prostate cancer patients (Cohort 1+2)

Patient Characteristics	CRPC-Adeno	CRPC-NE
Number of patients	39	8
Median age at diagnosis in years (range)	65 (45-80)	63 (57-67)
Median age at death in years (range)	72 (53-90)	71 (60-87)
Median survival after diagnosis in years (range)	8 (1-25)	5 (1-13)
Median PSA at death in ng/mL (range)	620.5 (5.63-15000)	3.3 (0.15-86.3)
Race: Caucasians (C) Others including African American, Hispanics, Asians (O)	C-34 O-5	C-7*
Gleason Score		
4-6	5	1
7	17	2
8-10	15	5
Unknown	2	-
Metastatic sites		
Lung	4	2
Liver	10	1
Lymph node (LN)	10	1
Others (Skin, Retroperitoneal, Periaortic LN, Retroperitoneal LN, Diaphragm, Retrosternal LN, Spleen, Omentum, Cortical, Pelvic LN, Mass)	15	4
Androgen Ablation Therapy		

Number of patients receiving androgen ablation therapy (%)	39 (100)	8 (100)
Number of patients receiving Enzalutamide, Abiraterone or both (%)	9 (23)	2 (25)
Other Therapies		
Ketoconazole (%)	18 (46)	1 (13)
DES (%)	15 (38)	1 (13)
Corticosteroids (%)	30 (77)	4 (50)
Estramustine (%)	5 (13)	1 (13)
Taxotere (%)	31	79) 4 (50)

*Race not known for 1 case